Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.61 |
| ▸ | FAP | Q12884 | 6/20 | 0.56 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL2964929 | 0.94 | DPP4 (0.55) | DPP4FAPDPP9CHRM1 | |
| SCHEMBL13200039 | 0.85 | DPP4 (0.64) | DPP4FAPDPP9CHRM1L3MBTL1 | |
| SCHEMBL13200040 | 0.84 | DPP4 (0.67) | DPP4FAPDPP9CHRM1 | |
| SCHEMBL13200030 | 0.84 | DPP4 (0.58) | DPP4FAPDPP9CHRM1L3MBTL1 | |
| SCHEMBL13200118 | 0.84 | DPP4 (0.58) | DPP4FAPDPP9CHRM1L3MBTL1 | |
| SCHEMBL13200044 | 0.84 | DPP4 (0.63) | DPP4FAPDPP9CHRM1 | |
| SCHEMBL13200328 | 0.84 | DPP4 (0.58) | DPP4FAPDPP9CHRM1L3MBTL1 | |
| SCHEMBL13200079 | 0.82 | DPP4 (0.61) | DPP4FAPDPP9CHRM1ALDH1A1 | |
| SCHEMBL13200414 | 0.82 | DPP4 (0.54) | DPP4FAPDPP9CHRM1 | |
| SCHEMBL13200083 | 0.82 | DPP4 (0.60) | DPP4FAPDPP9CHRM1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772226-B2 | Condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | DPP4, HDAC1, DPP7 | DPP4 1/4885FAP 3205/4885DPP9 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.